Nov 11, 2021 / 06:00PM GMT
Judah C. Frommer - Crédit Suisse AG - Research Division - Senior Analyst
Hi, everyone. Welcome back to Day 4 of the 2021 Credit Suisse Healthcare Conference. I'm Judah Frommer. I cover biotech here at CS, and we're happy to have Kymera with us. They'll start out with a presentation, and then we'll have some time for Q&A after. So Nello, why don't I pass it over to you?
Nello Mainolfi - Kymera Therapeutics, Inc. - Co-Founder, President, CEO & Director
Thanks, Judah. So thanks for the invitation. Great to be here. So what I thought I would do, just go through some slides maybe for the first 20, 25 minutes, and then we can leave time for questions. The team is online as well, if needed. So let me put the slides. So hopefully, that's visible to the audience.
So again, thanks for the invite. The goal today is just over a bit of history and why Kymera was founded, but then spend most of the time providing an update on what we've done really in the past, I would say a few weeks, if not months, and what we're expecting to see
Kymera Therapeutics Inc at Credit Suisse Healthcare Conference (Virtual) Transcript
Feb 07, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers